It is widely known that the extent of time spent in a state of hyperglycemia increases the risk of complications for patients with type 2 diabetes (T2D). However, despite the availability of many antihyperglycemic agents, success in managing T2D has not dramatically improved in recent years. Indeed, therapeutic inertia – the failure to initiate or intensify treatment – is a well-characterized phenomenon. In this roundtable, the speakers discuss the management of individuals with A1C ≥9% despite treatment with 2 or 3 oral antihyperglycemic agents, who represent a large patient population requiring treatment intensification.
Dr. Frias has received research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson and Johnson, Merck, Novo Nordisk, Pfizer, Sanofi, and Theracos. He is on the advisory boards and is a consultant for Boehringer Ingelheim, Eli Lilly, Johnson and Johnson, Merck, Novo Nordisk, and Sanofi. He is on the speakers’ bureaus for Merck and Sanofi.
Dr. Wright is on the advisory board for Abbott Diabetes Care. He is an advisor and consultant for Abbott Diabetes Care, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim/Lilly, Merck, Sanofi, and Voluntis. He is a speaker for Abbott Diabetes Care, Boehringer Ingelheim, and Boehringer Ingelheim/Lilly.
Ms. Whitmire has no conflicts of interest to disclose.
This roundtable was funded by Sanofi US, Inc. The authors received writing editorial support in the preparation of the material provided by Helen Jones, PhD, CMPP, of Evidence Scientific Solutions, funded by Sanofi US, Inc.